3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Hepatoblastoma
5
Colorectal Neoplasms
2
Colonic Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
PRETEXT I Hepatoblastoma
1
Neuroblastoma
1
Neoplasms
1
Fibrolamellar hepatocellular carcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
222
lenvatinib
147
Bevacizumab
131
Nivolumab
86
atezolizumab
80
pembrolizumab
74
Radiosurgery
71
durvalumab
63
sintilimab
61
Oxaliplatin
60
Fluorouracil
56
Doxorubicin
47
tislelizumab
46
apatinib
44
Radiofrequency Ablation
44
Hepatectomy
43
Leucovorin
41
camrelizumab
40
Radiotherapy
40
tremelimumab
37
Magnetic Resonance Spectroscopy
36
regorafenib
34
Capecitabine
30
Immune Checkpoint Inhibitors
29
Folfox protocol
29
Cisplatin
28
Gemcitabine
26
Cyclophosphamide
26
cabozantinib
25
Ipilimumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Vincristine
×
Gastrointestinal
×
Clear all
NCT03017326
2026-05-13
PHITT
University of Birmingham
Phase 3
Active not recruiting
450 enrolled